Targeted Interference with Signal Transduction Events
Sequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Berlin, Heidelberg :
Springer Berlin Heidelberg,
2007.
|
| Σειρά: | Resent Results in Cancer Research,
172 |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- Introduction: The Rationale for the Development of Targeted Drugs in Cancer Therapy
- Identifying Critical Signaling Molecules for the Treatment of Cancer
- Tyrosine Kinase Inhibitors and Cancer Therapy
- Targeting ERBB Receptors in Cancer
- Inhibition of the IGF-I Receptor for Treatment of Cancer. Kinase Inhibitors and Monoclonal Antibodies as Alternative Approaches
- Inhibition of the TGF-? Signaling Pathway in Tumor Cells
- The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition
- The Ras Signalling Pathway as a Target in Cancer Therapy
- The Mitogen-Activated Protein Kinase Pathway for Molecular-Targeted Cancer Treatment
- Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events.
